Max Robotics — Global Service Robot Directory + US Certification

About

Sabrina Forveille is a leading researcher in cancer immunology and autophagy, whose work has significantly advanced the understanding of how to harness the immune system against tumors. Her major contributions center on two key areas: oncolytic peptides and autophagy modulation. Forveille’s landmark 2016 study on the oncolytic peptide LTX-315, cited over 129 times, demonstrated that this agent triggers immunogenic cell death by selectively permeabilizing mitochondrial membranes, leading to a potent T-cell-mediated anticancer immune response. This work established a novel mechanism for converting dying tumor cells into in situ vaccines. More recently, her 2021 research on IGF1 receptor inhibition, with 77 citations, revealed that blocking this receptor amplifies the effects of cancer drugs through both autophagy-dependent and immune-mediated pathways, offering a dual strategy for therapy. Forveille also co-developed a high-throughput screening platform for autophagy, a critical tool for drug discovery. Her findings have profound implications for designing combination immunotherapies that exploit cell death and autophagy to overcome treatment resistance, marking her as a pivotal figure in translational cancer research.